TGF-beta(1) Genotype and Accelerated Decline in Lung Function of Patients with Cystic Fibrosis

Overview

Journal Thorax

Date 2000 May 19

PMID 10817792

Citations 71

Authors

P D Arkwright

S Laurie

M Super

V Pravica

M J Schwarz

A K Webb

I V Hutchinson

Affiliations

Soon will be listed here.

Abstract

Background: Polymorphisms in transforming growth factor (TGF)-beta(1) associated with variations in cytokine levels are linked to fibrosis in a number of tissues. However, the contribution of this cytokine to organ fibrosis in patients with cystic fibrosis is presently unclear. This study was undertaken to examine the association between TGF-beta(1) gene polymorphisms and the development of pulmonary dysfunction in patients with cystic fibrosis.

Methods: Polymorphisms in the TGF-beta(1) gene defining amino acids of codons 10 and 25 were determined by ARMS-PCR using DNA stored on 171 Caucasian patients who were homozygous for the DeltaF508 mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Clinical information on the patients was obtained from medical records.

Results: Patients with cystic fibrosis of a TGF-beta(1) high producer genotype for codon 10 had more rapid deterioration in lung function than those with a TGF-beta(1) low producer genotype. The relative risk of accelerated decline in forced expiratory volume in one second (FEV(1)) to 50% predicted and forced vital capacity (FVC) to 70% predicted of patients with a high producer genotype was 1.74 (95% CI 1.11 to 2. 73) compared with 1.95 (95% CI 1.24 to 3.06) for those with a low producer genotype.

Discussion: TGF-beta(1) genotypes may have a role in mediating pulmonary dysfunction in patients with cystic fibrosis. Further work is required to determine whether inhibition of TGF-beta(1) activity in these patients may slow disease progression.

Citing Articles

LMTK2 switches on canonical TGF-β1 signaling in human bronchial epithelial cells.

Cruz D, Donovan J, Hejenkowska E, Mu F, Banerjee I, Kohn M Am J Physiol Lung Cell Mol Physiol. 2024; 327(5):L769-L782.

PMID: 39316683 PMC: 11560069. DOI: 10.1152/ajplung.00034.2024.

IL1B gene variants, but not TNF, CXCL8, IL6 and IL10, modify the course of cystic fibrosis in Polish patients.

Zakerska-Banaszak O, Gozdzik-Spychalska J, Gabryel M, Zuraszek J, Skrzypczak-Zielinska M, Slomski R F1000Res. 2024; 11:379.

PMID: 39185143 PMC: 11344199. DOI: 10.12688/f1000research.110472.3.

Epithelial-Mesenchymal Transition Mechanisms in Chronic Airway Diseases: A Common Process to Target?.

Mottais A, Riberi L, Falco A, Soccal S, Gohy S, De Rose V Int J Mol Sci. 2023; 24(15).

PMID: 37569787 PMC: 10418908. DOI: 10.3390/ijms241512412.

Furin as a therapeutic target in cystic fibrosis airways disease.

Douglas L, Reihill J, Montgomery B, Martin S Eur Respir Rev. 2023; 32(168).

PMID: 37137509 PMC: 10155048. DOI: 10.1183/16000617.0256-2022.

Mucosal Immunity in Cystic Fibrosis.

Bojanowski C, Lu S, Kolls J J Immunol. 2022; 207(12):2901-2912.

PMID: 35802761 PMC: 9270582. DOI: 10.4049/jimmunol.2100424.

References

Perrey C, Turner S, Pravica V, Howell W, Hutchinson I . ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol. 1999; 7(2):127-8. DOI: 10.1016/s0966-3274(99)80030-6. View

Kanzler S, Lohse A, Keil A, Henninger J, Dienes H, Schirmacher P . TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol. 1999; 276(4):G1059-68. DOI: 10.1152/ajpgi.1999.276.4.G1059. View

Roberts A, Lamb L, Newton D, Sporn M, De Larco J, Todaro G . Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc Natl Acad Sci U S A. 1980; 77(6):3494-8. PMC: 349643. DOI: 10.1073/pnas.77.6.3494. View

Ignotz R, Massague J . Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem. 1986; 261(9):4337-45. View

Phan S, Kunkel S . Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res. 1992; 18(1):29-43. DOI: 10.3109/01902149209020649. View

Corrin B, Butcher D, McAnulty B, duBois R, Black C, Laurent G . Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology. 1994; 24(2):145-50. DOI: 10.1111/j.1365-2559.1994.tb01293.x. View

Kopp J, Factor V, Mozes M, Nagy P, Sanderson N, Bottinger E . Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest. 1996; 74(6):991-1003. View

Zielenski J, Tsui L . Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet. 1995; 29:777-807. DOI: 10.1146/annurev.ge.29.120195.004021. View

Franko A, Sharplin J, Ghahary A, Barcellos-Hoff M . Immunohistochemical localization of transforming growth factor beta and tumor necrosis factor alpha in the lungs of fibrosis-prone and "non-fibrosing" mice during the latent period and early phase after irradiation. Radiat Res. 1997; 147(2):245-56. View

10.

Bayer E, Herr W, Kanzler S, Waldmann C, Meyer zum Buschenfelde K, Dienes H . Transforming growth factor-beta1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity. J Hepatol. 1998; 28(5):803-11. DOI: 10.1016/s0168-8278(98)80230-4. View

11.

El-Gamel A, Awad M, Sim E, Hasleton P, Yonan N, Egan J . Transforming growth factor-beta1 and lung allograft fibrosis. Eur J Cardiothorac Surg. 1998; 13(4):424-30. DOI: 10.1016/s1010-7940(98)00048-7. View

12.

Awad M, El-Gamel A, Hasleton P, Turner D, Sinnott P, Hutchinson I . Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation. 1998; 66(8):1014-20. DOI: 10.1097/00007890-199810270-00009. View

13.

Perrey C, Pravica V, Sinnott P, Hutchinson I . Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: a technical report. Transpl Immunol. 1998; 6(3):193-7. DOI: 10.1016/s0966-3274(98)80045-2. View

14.

Grainger D, Heathcote K, Chiano M, Snieder H, Kemp P, Metcalfe J . Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet. 1999; 8(1):93-7. DOI: 10.1093/hmg/8.1.93. View

15.

Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H . Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci U S A. 1999; 96(5):2345-9. PMC: 26786. DOI: 10.1073/pnas.96.5.2345. View